Do you want to read an article? Please log in or register.
Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity
Breast Cancer
Related content
SABCS 2025
Breast Cancer
NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer
Breast Cancer
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
Cancer Treat Rev
Yuan Y, Long X, Wei M, Chen L, Zhang J, Liu X
doi: 10.1016/j.ctrv.2025.102975
ESMO 2025
Breast Cancer
NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer
Breast Cancer
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up
J Natl Cancer Inst
Danielsson O, Dar H, Nordenskjöld A, Perez-Tenorio G, Nordenskjöld B, Fornander T, Stål O, Tobin NP, Tutzauer J, Johansson A, Lindström LS
doi: 10.1093/jnci/djag049
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
RECOMMENDED
Breast Cancer
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
doi: 10.1200/JCO-25-01660
Breast Cancer
Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
healthbook TIMES Onco Hema
Vetter M, Kurzeder C
doi: 10.36000/HBT.OH.2025.24.183
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
SPECIAL REPORT
Breast Cancer